ConsejoSano is the leading Hispanic health platform in the US, helping clients to increase engagement, simplify care, and lower costs related to their Spanish-speaking members. We’re on a mission to remove the #1 cause of healthcare disparities language and culture barriers and to help people live better, healthier lives.
Our current services include telehealth, care navigation, and outbound engagement and education campaigns, all of which are delivered by native Spanish-speaking, Hispanic doctors. Our service is totally unique in the US healthcare market, which gives us the opportunity to build an extremely valuable business while providing a life changing resource to underserved communities.
We have a client list that includes some of the leading employers, health plans, and IPAs in the country, and a technical platform that is secure, flexible, and built to scale quickly. With over 30,000 members and partnerships with Mercer and other key channel partners, we have significant traction and are poised for a period of rapid growth across all verticals.
|HQ||San Francisco, US||Map|
|Employees (est.) (Feb 2019)||20|
ConsejoSano total Funding
ConsejoSano latest funding size
Time since last funding
|2 years ago|
|Startupbootcamp Digital Health Miami, The Impact Engine, 7wire Ventures, Tufts Health Plan, Wanxiang Healthcare Investments, TOTAL Impact Capital, Oxeon Partners, Acumen|
ConsejoSano has 629 Twitter Followers. The number of followers has increased 1.5% month over month and increased 3.6% quarter over quarter
When was ConsejoSano founded?
ConsejoSano was founded in 2014.
Who are ConsejoSano key executives?
ConsejoSano's key executives are Abner Mason, Joel Garcia and Robyn LaMont.
How many employees does ConsejoSano have?
ConsejoSano has 20 employees.
Who are ConsejoSano competitors?
Competitors of ConsejoSano include Doctor Insta, Two Pore Guys and Accelerate Diagnostics.
Where are ConsejoSano offices?
ConsejoSano has an office in San Francisco.
How many offices does ConsejoSano have?
ConsejoSano has 1 office.